2-甲基-5-(甲基磺酰基)苯-1-磺酰氯 | 2224-67-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-5-(甲基磺酰基)苯-1-磺酰氯
• 英文名称: 5-methanesulfonyl-2-methylbenzenesulfonyl chloride
• 英文别名: 5-Methylsulfonyl-2-methyl-benzolsulfonylchlorid；3-Chlorsulfonyl-4-methylphenylmethylsulfon；2-methyl-5-(methylsulfonyl)benzenesulfonyl chloride；5-Methanesulfonyl-2-methylbenzene-1-sulfonyl chloride；2-methyl-5-methylsulfonylbenzenesulfonyl chloride
• CAS: 2224-67-1
• 化学式: C₈H₉ClO₄S₂
• mdl: MFCD00085947
• 分子量: 268.742
• InChiKey: UAPXGQGQLFOWOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  85
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2904909090

反应信息

• 作为反应物：
  描述：

  2-甲基-5-(甲基磺酰基)苯-1-磺酰氯 在 ammonium hydroxide 作用下， 生成 2-甲基-5-(甲基磺酰基)苯磺酰胺
  参考文献：
  名称：

  Kugita,H. et al., Chemical and pharmaceutical bulletin, 1962, vol. 10, p. 1001 - 1008

  摘要：

  DOI：
• 作为产物：
  描述：

  对甲砜基甲苯 在 氯磺酸 作用下， 反应 2.17h， 以83%的产率得到2-甲基-5-(甲基磺酰基)苯-1-磺酰氯
  参考文献：
  名称：

  Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR

  摘要：

  Structure-activity relationship studies of the pyrazolo[1,5-a]pyridine class of PI3 kinase inhibitors show that substitution off the hydrazone nitrogen and replacement of the sulfonyl both gave a loss of p110 alpha selectivity, with the exception of an N-hydroxyethyl analogue. Limited substitutions were tolerated around the phenyl ring; in particular the 2,5-substitution pattern was important for PI3 kinase activity. The N-hydroxyethyl compound also showed good inhibition of cell proliferation and inhibition of phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity. It had suitable pharmacokinetics for evaluation in vivo, and showed tumour growth inhibition in two human tumour cell lines in xenograft studies. This work has provided suggestions for the design of more soluble analogues. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.031

文献信息

• Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase
  作者：Katherine A. Hurley、Thiago M. A. Santos、Molly R. Fensterwald、Madhusudan Rajendran、Jared T. Moore、Edward I. Balmond、Brice J. Blahnik、Katherine C. Faulkner、Marie H. Foss、Victoria A. Heinrich、Matthew G. Lammers、Lucas C. Moore、Gregory D. Reynolds、Galen P. Shearn-Nance、Brian A. Stearns、Zi W. Yao、Jared T. Shaw、Douglas B. Weibel

  DOI：10.1039/c7md00012j

  日期：——

  potent inhibitors of DNA gyrase and are active against clinical strains of Gram-negative bacteria (Escherichia coli, Shigella flexneri, and Salmonella enterica; 3 of 10 wild-type strains tested) and Gram-positive bacteria (Bacillus spp., Enterococcus spp., Staphylococcus spp., and Streptococcus spp.; all 9 of the wild-type strains tested). E. coli strains resistant to the DNA gyrase inhibitors ciprofloxacin

  细菌DNA促旋酶是一种必不可少的II型拓扑异构酶，可使细胞克服复制，转录，重组和修复过程中遇到的拓扑障碍。该酶在细菌中无处不在，代表了抗菌治疗的重要临床目标。在本文中，我们从183个衍生物库中报告了三种激动人心的新型回旋酰胺类似物的表征，它们是DNA回旋酶的有效抑制剂，对革兰氏阴性菌（大肠杆菌，志贺氏志贺氏菌和肠炎沙门氏菌；测试的10种野生型菌株中有3种）和革兰氏阳性菌（芽孢杆菌，肠球菌，葡萄球菌spp。，and Streptococcus spp .; 所有9种野生型菌株都进行了测试）。对DNA促旋酶抑制剂环丙沙星和新霉素具有抗性的大肠杆菌菌株对这些新的乙二酰胺具有极小的交叉抗性。体外研究表明，新的类似物可有效抑制DNA促旋酶的DNA超螺旋活性（IC 50值为47–170 nM），但不会改变酶的ATPase活性。尽管赋予细菌细胞对这些新的回旋酰胺抗性的突变会映射到编码DNA回旋酶亚基的基
• [EN] PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY<br/>[FR] PYRAZOLO[1,5-A]PYRIDINES ET LEUR UTILISATION EN CANCÉROTHÉRAPIE
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2009008748A1

  公开（公告）日：2009-01-15

  Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  Pyrazolo[1,5-a]吡啶类化合物被描述，包括它们的制备方法，以及它们作为抗癌治疗药物或药剂的用途，无论是单独使用还是与放疗和/或其他抗癌药物联合使用。
• BENZOCYCLOHEPTENE ACETIC ACIDS
  申请人：Firooznia Fariborz

  公开号：US20120309796A1

  公开（公告）日：2012-12-06

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

  本文提供的是化合物的公式(I)以及其药用盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗炎症性疾病和紊乱，如哮喘和慢性阻塞性肺病等，具有用处。
• [EN] DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS<br/>[FR] DÉRIVÉS DES BENZOTHIAZINES, LEUR PRÉPARATION ET LEUR APPLICATION EN TANT QUE MÉDICAMENTS
  申请人：PF MEDICAMENT

  公开号：WO2010100139A1

  公开（公告）日：2010-09-10

  The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11β-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or an ether. R2 represents a naphthyl or a 1, 2, 3, 4-tetrahydro-naphthalene or a biphenyl or phenyl pyridine or a substituted phenyl. R3 represents a methyl or ethyl; R4 and R'4 represent a hydrogen.

  本发明的目标是具有抑制11β-HSD1酶级别和细胞级别的能力的苯并噻嗪衍生物。本发明的化合物具有一般式(I)。其中，显著地，R1代表氢或OR1代表酯或醚。R2代表萘基或1,2,3,4-四氢萘基或联苯基或苯基吡啶或取代苯基。R3代表甲基或乙基；R4和R'4代表氢。
• Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions
  申请人：Subasinghe L. Nalin

  公开号：US20070066667A1

  公开（公告）日：2007-03-22

  Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R a , R b , and R c are defined in the specification, as are A Z, Q, R 1 and R 2 .

  本发明涉及一种用于治疗由补体级联经典途径介导的急性或慢性疾病症状的化合物。所述化合物为I式的化合物或其溶剂化物、水合物、药学上可接受的盐或前药；其中Ra、Rb和Rc在规范中定义，A、Z、Q、R1和R2也在规范中定义。